These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1075 related articles for article (PubMed ID: 31319999)
1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999 [TBL] [Abstract][Full Text] [Related]
2. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms]. Li Y; Zhang FS; Guo L; Ying JM Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169 [No Abstract] [Full Text] [Related]
3. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related]
4. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes. Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618 [TBL] [Abstract][Full Text] [Related]
5. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340 [TBL] [Abstract][Full Text] [Related]
6. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076 [TBL] [Abstract][Full Text] [Related]
7. Treatment with Next-Generation ALK Inhibitors Fuels Plasma Dagogo-Jack I; Rooney M; Lin JJ; Nagy RJ; Yeap BY; Hubbeling H; Chin E; Ackil J; Farago AF; Hata AN; Lennerz JK; Gainor JF; Lanman RB; Shaw AT Clin Cancer Res; 2019 Nov; 25(22):6662-6670. PubMed ID: 31358542 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925 [TBL] [Abstract][Full Text] [Related]
9. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment. Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198 [TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719 [TBL] [Abstract][Full Text] [Related]
12. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703 [TBL] [Abstract][Full Text] [Related]
13. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444 [TBL] [Abstract][Full Text] [Related]
14. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733 [TBL] [Abstract][Full Text] [Related]
15. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
16. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer. Lin YT; Ho CC; Hsu WH; Liao WY; Yang CY; Yu CJ; Tsai TH; Yang JC; Wu SG; Hsu CL; Hsieh MS; Huang YL; Wu CL; Shih JY Cancer Med; 2024 Jan; 13(1):e6870. PubMed ID: 38140788 [TBL] [Abstract][Full Text] [Related]
17. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836 [TBL] [Abstract][Full Text] [Related]
19. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [TBL] [Abstract][Full Text] [Related]
20. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Iwama E; Sakai K; Azuma K; Harada D; Nosaki K; Hotta K; Nishio M; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I Cancer Sci; 2018 Dec; 109(12):3921-3933. PubMed ID: 30289575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]